» Articles » PMID: 16863739

Maximum Standard Uptake Value of Mediastinal Lymph Nodes on Integrated FDG-PET-CT Predicts Pathology in Patients with Non-small Cell Lung Cancer

Overview
Journal Ann Thorac Surg
Publisher Elsevier
Date 2006 Jul 26
PMID 16863739
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Positron emission tomography (PET) scans often help direct biopsies of mediastinal lymph nodes in patients with non-small cell lung cancer (NSCLC), but the maximum standard uptake value (maxSUV) of individual nodes has not been evaluated.

Methods: This is a prospective study of consecutive patients with NSCLC, all of whom underwent integrated fluorodeoxyglucose-positron emission-computed tomography (FDG-PET-CT) and had biopsy or resection of their mediastinal lymph nodes.

Results: There were 397 patients. One-hundred and forty-three patients had N2 disease and 1,252 N2 nodes were pathologically examined. The median maxSUV of the nodes that had metastatic disease were the following: for the 2R node, 10.4 (range, 0-18.6); for 4R, 8.6 (range, 0-18.3); for 5, 8.9 (range, 0-26.3); for 6, 7.6 (range, 0-19.6); for 7, 7.7 (range, 0-14); for 8 and 9, 5.4 (range, 0-8.9). The median maxSUV for all of the N2 nodes that were benign was 0 (range, 0-18.8) (p < 0.05 for all stations except for nodes 8 and 9). When a maxSUV of 5.3 is used the accuracy of integrated FDG-PET-CT for each N2 nodal station is maximized and is at least 92% for each.

Conclusions: The maxSUV of individual mediastinal lymph nodes is a predictor of malignancy. There is overlap between false and true positives. Definitive biopsies are required to prove cancer irrespective of the maxSUV value. However, when a maxSUV of 5.3 is used instead of the traditional value of 2.5, the accuracy for FDG-PET-CT for each N2 nodal station increases to at least 92%.

Citing Articles

Peripheral Circulating Blood Cells Deviation Based on Tumor Inflammatory Microenvironment Activity in Resected Upstaged Lung Adenocarcinomas.

Bonis A, Lunardi F, Pagliarini G, Verzeletti V, Lione L, Busetto A J Clin Med. 2025; 13(24.

PMID: 39768520 PMC: 11676159. DOI: 10.3390/jcm13247597.


Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review.

Wu Y, Shang J, Zhang X, Li N J Nanobiotechnology. 2024; 22(1):783.

PMID: 39702277 PMC: 11657939. DOI: 10.1186/s12951-024-02940-4.


Evaluation of hypermetabolic mediastinal-hilar lymph nodes determined by PET/CT with EBUS-TBNA and calculation of SUVmax cutoff values in differentiation of malignancy.

Ugurlu E, Metin M, Cetin N, Kilicarslan E, Degirmencioglu S, Sengoz T Medicine (Baltimore). 2023; 102(35):e34928.

PMID: 37657039 PMC: 10476785. DOI: 10.1097/MD.0000000000034928.


The value on SUV-derived parameters assessed on F-FDG PET/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer.

Liao X, Liu M, Li S, Huang W, Guo C, Liu J BMC Med Imaging. 2023; 23(1):49.

PMID: 37020286 PMC: 10077668. DOI: 10.1186/s12880-023-01004-7.


Usefulness of pyruvate dehydrogenase-E1α expression to determine SUVmax cut-off value of [F]FDG-PET for predicting lymph node metastasis in lung cancer.

Ito R, Yashiro M, Tsukioka T, Izumi N, Komatsu H, Inoue H Sci Rep. 2023; 13(1):1565.

PMID: 36709375 PMC: 9884208. DOI: 10.1038/s41598-023-28805-8.